Posts in Commercialization
Food Safety of Fermented Proteins and Cultivated Meat and Seafood

Food Safety of Fermented Proteins and Cultivated Meat and Seafood, written by Kimberly J. Ong, Fiona Case and Jo Anne Shatkin from Vireo Advisors, chapter 6 in Cellular Agriculture Technology, Society, Sustainability and Science published by Elsevier, reviews potential hazards specific to the manufacture and consumption of fermented proteins and cultivated meat and seafood….

Read More
Vireo Advisors, LLC Joins Cellular Agriculture Canada initiative with New Harvest

Cellular Agriculture Canada has been re-launched as a multi-stakeholder coalition led by New Harvest Canada joined by Vireo Advisors, LLC. The mandate of the group is the directive that Canada can capitalize on the global movement to achieve a net-zero economy by leveraging its strengths in the emerging field of cellular agriculture.  

Read More
Cultured meat: commercialization and regulatory roundup

At Vireo, we keep close surveillance on commercialization and regulatory developments in cultured and alt-protein meat and seafood, and we have rarely seen as much activity as this! Here is our roundup of the latest developments…

Read More
Climate change is a real business risk that can be managed.

In recent weeks we have seen U.S. Senators call climate change ‘ideology’, but overwhelming evidence reveals climate change as a real business risk – one that can, and must, be managed. At Vireo, we are working to gain market and regulatory acceptance of biobased, recycled, and advanced technologies that lower these risks.

Read More
View Dr. Kimberly Ong’s “Solving for Safety” Presentation from the New Harvest 2022: Experience Cellular Agriculture Conference

During the New Harvest 2022: Experience Cellular Agriculture Conference, Dr. Kimberly Ong of Vireo Advisors, LLC discussed how to bring safe products to market by evaluating and demonstrating safety in her presentation “Solving for Safety”.

Read More
FDA enforcement discretion and faster new product approval to increase infant formula supply in the U.S.

A voluntary recall and facility shutdown by Abbott Nutrition has created a supply disruption for certain types of infant formula. President Biden has announced a series of measures to address the resulting crisis for families around the country, including action by the FDA help make up the shortfall.

Read More
Achieving the potential of the US bioeconomy

The US bioeconomy (biotechnology-based economic activity) currently contributes 5.1 percent or more of US GDP and has tremendous growth potential. Realizing that potential requires, among other efforts, investment by the government to advance innovation infrastructure including regulatory frameworks that are open to new technologies and don’t obstruct them.

Read More